ROCKVILLE, Md., June 3, 2019 /PRNewswire/ -- CASI
Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical
company with a platform to develop and accelerate the launch of
innovative therapeutics and pharmaceutical products in China, the U.S., and throughout the world,
announces it will present at the 2019 BIO International Convention
being held June 3-6, 2019 in
Philadelphia, PA.
Event: BIO International Convention
Date: Tuesday, June 4, 2019
Time: 3:45PM (Eastern Time)
Presenter: James E. Goldschmidt,
Ph.D.
Presentation Room: Theater 2, Pennsylvania Convention Center (PCC)
A copy of the presentation materials will be made available
directly through the Investor Relations section of the company's
website, www.casipharmaceuticals.com, on June 4, 2019.
About CASI Pharmaceuticals
CASI Pharmaceuticals is a U.S. biopharmaceutical company with a
platform to develop and accelerate the launch of pharmaceutical
products and innovative therapeutics in China, the U.S., and throughout the
world. CASI's product pipeline features (i) CID-103, an
anti-CD38 monoclonal antibody being developed for the treatment of
hematological cancers; (ii) China
regional rights to three U.S. Food and Drug Administration
(FDA)-approved drugs (EVOMELA®) (melphalan hydrochloride
for injection) approved by China's
National Medical Products Administration (NMPA) for marketing,
ZEVALIN® (ibritumomab tiuxetan) and MARQIBO®
(vincristine sulfate LIPOSOME injection) approved by NMPA for
registration confirmatory trials in China; and (iii) a portfolio of FDA-approved
and pending abbreviated new drug applications (ANDAs). CASI
has offices in Rockville, Maryland
and a wholly owned subsidiary in Beijing,
China through which substantially all of our operations are
conducted. More information on CASI is available at
www.casipharmaceuticals.com.
Forward-Looking Statements
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act with
respect to the outlook for expectations for future financial or
business performance, strategies, expectations and goals.
Forward-looking statements are subject to numerous assumptions,
risks and uncertainties, which change over time. Forward-looking
statements speak only as of the date they are made, and no duty to
update forward-looking statements is assumed. Actual results
could differ materially from those currently anticipated due to a
number of factors, including: the difficulty of
executing our business strategy in China; our lack of experience in manufacturing
products and uncertainty about our resources and capabilities to do
so on a clinical or commercial scale; risks relating to the
commercialization, if any, of our products and proposed products
(such as marketing, safety, regulatory, patent, product liability,
supply, competition and other risks); our inability to predict when
or if our product candidates will be approved for marketing by the
FDA, NMPA, or other regulatory authorities; our
inability to enter into strategic partnerships for the development,
commercialization, manufacturing and distribution of our proposed
product candidates or future candidates; the volatility in the
market price of our common stock; risks relating to the need for
additional capital and the uncertainty of securing additional
funding on favorable terms; risks associated with CID-103 and our
product candidates; risks associated with CID-103 and our other
early-stage products under development; risks that results in
preclinical and early clinical models are not necessarily
indicative of later clinical results; uncertainties relating to
preclinical and clinical trials, including delays to the
commencement of such trials; the lack of success in the clinical
development of any of our products; and our dependence on third
parties. Such factors, among others, could have a material
adverse effect upon our business, results of operations and
financial condition. We caution readers not to place undue
reliance on any forward-looking statements, which only speak as of
the date made. Additional information about the factors and risks
that could affect our business, financial condition and results of
operations, are contained in our filings with the U.S. Securities
and Exchange Commission, which are available at www.sec.gov.
EVOMELA®, Marqibo®
and Zevalin® are proprietary to
Acrotech Biopharma LLC and its affiliates.
COMPANY
CONTACT:
CASI
Pharmaceuticals, Inc.
240.864.2643
ir@casipharmaceuticals.com
|
INVESTOR
CONTACT:
Solebury
Trout
Jennifer
Porcelli
646.378.2962
jporcelli@troutgroup.com
Brennan
Doyle
617.221.9005
BDoyle@troutgroup.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/casi-pharmaceuticals-to-present-at-the-2019-bio-international-convention-300859984.html
SOURCE CASI Pharmaceuticals, Inc.